MONTREAL, October 7, 2025 – CSL Behring Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) have announced signing of a Letter of Intent that sets pricing...
MONTRÉAL, September 19, 2025 – No announcements have been made over the summer on progress in gaining access to two novel hemophilia therapies. Altuviiio for...
MONTRÉAL, July 3, 2025 – In June, both Canada’s Drug Agency (CDA) and Quebec’s Institut national d’excellence en santé et en services sociaux (INESSS) released...
MONTRÉAL, March 31, 2025 – Health Canada has granted marketing approval to Altuviiio (efanesoctocog alfa) for the treatment of hemophilia A in children, adolescents and...
MONTREAL, March 12, 2025 – Results from the HOPE-B trial for the hemophilia B gene therapy, Hemgenix, show steady expression of factor IX (FIX) four...